Trial Profile
A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Bleselumab (Primary) ; Basiliximab; Meprednisone; Meprednisone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Tacrolimus; Tacrolimus
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 12 Jul 2021 Status changed from active, no longer recruiting to completed.
- 10 May 2021 Planned End Date changed from 7 Oct 2021 to 31 Oct 2021.
- 08 Mar 2021 Planned End Date changed from 1 Jan 2022 to 7 Oct 2021.